---
document_datetime: 2026-02-11 09:00:08
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/plegridy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: plegridy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0934051
conversion_datetime: 2026-02-13 18:33:04.870682
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Plegridy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | B.I.b.1 Change in the specification | 09/02/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323944                     | parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Refused                                                                                                                                                                                                                                                                                                                                                          |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000314831 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in- process limits - Accepted | 15/12/2025 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Variation type II / EMA/VR/0000286235 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.b Implementation of change(s) which require to be further substantiated by new additional                                                                                                                                   | 11/12/2025 | SmPC and PL | Sections 5.1, 5.2, and 4.8 are updated to inform about study design features of the randomised, open-label active-controlled (interferon beta-1a) parallel group study in patients with RRMS aged 10 to less than 18 years of age (section 5.1) and main pharmacokinetics (section 5.2), efficacy (section 5.1) and safety (section 4.8) results in this study. Section 4.2 is updated to inform that in spite of the above information, the safety and efficacy of peginterferon beta1a in children and adolescents |

<div style=\"page-break-after: always\"></div>

|                                       | data to be submitted by the MAH - Accepted Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on interim results from study 105MS306. This is an open-label, randomized, multicenter, active-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of BIIB017 in pediatric subjects aged 10 to less than 18 years for the treatment of relapsing- remitting multiple sclerosis, with optional open-label extension. The PL is updated accordingly.                                                                                                                                                                                                                      |            | have not been established in multiple sclerosis For more information, please refer to the Summary of Product Characteristics.                                                                                                                                    |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000307743 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (Type IB) - To update the RMP by updating the study status and milestones for study 105MS404, drug utilization in pregnancy exposure in second and third trimester of pregnancy, in line with the agreed protocol Version 3.0, submitted within procedure EMA/PAM0000263236. In addition, the MAH took the opportunity to (1) Update the QPPV details, (2) Remove post authorisation exposure data by country (per guidance on anonymisation of personal | 14/11/2025 | To update the RMP by updating the study status and milestones for study 105MS404, drug utilization in pregnancy exposure in second and third trimester of pregnancy, in line with the agreed protocol Version 3.0, submitted within procedure EMA/PAM0000263236. |

<div style=\"page-break-after: always\"></div>

|                                       | data, reference EMA/63692/2025, revision 3), (3) Update post authorisation exposure estimates based on the new data lock point, (4) Update clinical trial exposure based on the new data lock point, and (5) Template changes: Include a row for Section VII in the Summary of Significant Changes, confidentiality statements removed.                                                                                                                                                                                   |            |          |                   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------|-------------------|
| Variation type IA /                   | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 16/10/2025 | Annex II | EMA/VR/0000300515 |
| Variation type IA / EMA/VR/0000300753 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.c Deletion of a non-significant in-process test - Accepted                                                                                                                                                                                                                                                                                                                                                | 24/09/2025 |          |                   |
| Variation type IB / EMA/VR/0000263823 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control                                                                                                                                                                                                                                                                                                          | 13/05/2025 |          |                   |

<div style=\"page-break-after: always\"></div>

| testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|